H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Cautious Hold Rating on Agenus Amid Strategic Realignment and Financial Challenges
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
Express News | Agenus Inc: To Sharpen Its Focus on Botensilimab/Balstilimab (BOT/Bal) in Mss Colorectal Cancer
Express News | Agenus Inc - Plan Includes 60% Reduction in Annual External Expenditures
Express News | Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment